Back to search results

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

B-cell Acute Lymphoblastic Leukemia · Large B-cell Lymphoma · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Marginal Zone Lymphoma · Follicular Lymphoma · Mantle Cell Lymphoma · Diffuse Large B Cell Lymphoma · High-grade B-cell Lymphoma · Burkitt Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL) · Non Hodgkin Lymphoma · Mixed Phenotype Acute Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Anthony Stein, MD) · AStein@coh.org · 877-467-3411
    Contact: Principal Investigator (Anthony Stein, MD)

  • Valkyrie Clinical Trials, Los Angeles, California, United States

    Contact: Study coordinator (Myo Zaw) · clinicaltrials@vctcare.com · 424-535-1874

  • Colorado Blood Cancer Institute, Denver, Colorado, United States

    Contact: Study coordinator (Clinical Trial Information Line) · 720-754-4835

  • New York Medical College, Valhalla, New York, United States

    Contact: Study coordinator (Mitchell Cairo, MD) · mitchell_cairo@nymc.edu · 914-594-2150
    Contact: Study coordinator (Lauren Harrison) · lauren_harrison@nymc.edu
    Contact: Principal Investigator (Mitchell Cairo, MD)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Lacey Williams, MD) · Lacey_Williams@med.unc.edu · 919-445-9676

  • The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

    Contact: Study coordinator (Gregory Behbehani, MD, PhD) · gregory.behbehani@osumc.edu · 614-293-3316

  • Oregon Health & Science University, Portland, Oregon, United States

    Contact: Study coordinator (Knight Cancer Institute Clinical Trials) · trials@ohsu.edu · 503-949-1080

  • TriStar BMT, Nashville, Tennessee, United States

    Contact: Study coordinator (Stephen Strickland, MD) · stephen.strickland@hcahealthcare.com · 615-329-7274

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Nicholas J Short, MD) · NShort@Mdanderson.org · 713-563-4485
Study leads

  • Vironexis Clinical Trials

    Study Director

    Vironexis Biotherapeutics Inc.

View source on ClinicalTrials.gov(opens in a new tab)